Literature DB >> 8666343

n-Butyrate induces plasminogen activator inhibitor type 1 messenger RNA in cultured Hep G2 cells.

T J Smith1, J J Piscatelli, V Andersen, H S Wang, P Lance.   

Abstract

n-Butyrate, a short-chain aliphatic carboxylic acid with pleiotropic actions, is present at high concentrations in the portal circulation and thus may play an important role in the regulation of specific gene expression in the mammalian liver. We report here that n-butyrate can increase substantially the level of plasminogen activator inhibitor type 1 (PAI-1) messenger RNA (mRNA) in Hep G2 cells, up to eightfold above control cultures. Maximal effects occurred at a concentration of 3 mmol/L n-butyrate and with a treatment period of 8 to 12 hours. Increases in PAI-1 mRNA were accompanied by modest increases (twofold) in the encoded protein as assessed by specific enzyme-linked immunosorbent assay and by [35S]methionine incorporation into immunoprecipitable PAI-1 in the culture medium. Nuclear run-on studies showed that the rate of transcription of the PAI-1 gene did not appear altered by treatment with 3 mmol/L n-butyrate for 6 hours. The increases in steady-state PAI-1 mRNA caused by exposure to n-butyrate can be blocked by cycloheximide. Enhanced stability of mature PAI-1 transcript could not be demonstrated in Hep G2 cells treated with the carboxylic acid. We have reported previously that n-butyrate can reduce the level of beta-galactoside alpha 2,6-sialyltransferase expression in Hep G2 cells. That effect was attenuated with inhibitors of protein and RNA synthesis and was mediated at the post-transcriptional level. Thus, n-butyrate can influence the expression of multiple genes in this hepatoblastoma cell through its actions on events that appear to be posttranscriptional. These observations may be relevant to the normal physiology of the mammalian liver because of the high concentrations of n-butyrate and related compounds to which the organ is ordinarily exposed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8666343     DOI: 10.1002/hep.510230430

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  4 in total

1.  The enhancement of phase 2 enzyme activities by sodium butyrate in normal intestinal epithelial cells is associated with Nrf2 and p53.

Authors:  Keisuke Yaku; Yuka Enami; Chika Kurajyo; Isao Matsui-Yuasa; Yotaro Konishi; Akiko Kojima-Yuasa
Journal:  Mol Cell Biochem       Date:  2012-07-18       Impact factor: 3.396

2.  Homologous upregulation of gonadotropin-releasing hormone receptor mRNA occurs through transcriptional activation rather than modulation of mRNA stability.

Authors:  M Cheon; D Park; Y Park; K Kam; S D Park; K Ryu
Journal:  Endocrine       Date:  2000-08       Impact factor: 3.633

3.  Butyrate reduces liver metastasis of rat colon carcinoma cells in vivo and resistance to oxidative stress in vitro.

Authors:  Xiaotong Li; Idun M Mikkelsen; Bente Mortensen; Jan-Olof Winberg; Nils-Erik Huseby
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  Na-butyrate increases the production and alpha2,6-sialylation of recombinant interferon-gamma expressed by alpha2,6- sialyltransferase engineered CHO cells.

Authors:  D Lamotte; L Buckberry; L Monaco; M Soria; N Jenkins; J M Engasser; A Marc
Journal:  Cytotechnology       Date:  1999-01       Impact factor: 2.058

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.